{"title":"STAT3信号的最新进展:癌症治疗的当前挑战和未来方向","authors":"K. Taniguchi, M. Tsugane, A. Asai","doi":"10.33696/signaling.2.050","DOIUrl":null,"url":null,"abstract":"Due to its importance in a wide range of cellular processes, including cell proliferation, apoptosis, and immune evasion, the signal transducer and activator of transcription (STAT) 3 signaling pathway has been studied intensively over the past few decades. Dysregulation of the STAT3 signaling pathway is closely associated with initiation and development of various types of hematologic or solid malignancies (approximately 70% of those appearing in humans) [1].","PeriodicalId":73645,"journal":{"name":"Journal of cellular signaling","volume":"11 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"A Brief Update on STAT3 Signaling: Current Challenges and Future Directions in Cancer Treatment\",\"authors\":\"K. Taniguchi, M. Tsugane, A. Asai\",\"doi\":\"10.33696/signaling.2.050\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Due to its importance in a wide range of cellular processes, including cell proliferation, apoptosis, and immune evasion, the signal transducer and activator of transcription (STAT) 3 signaling pathway has been studied intensively over the past few decades. Dysregulation of the STAT3 signaling pathway is closely associated with initiation and development of various types of hematologic or solid malignancies (approximately 70% of those appearing in humans) [1].\",\"PeriodicalId\":73645,\"journal\":{\"name\":\"Journal of cellular signaling\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cellular signaling\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33696/signaling.2.050\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cellular signaling","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33696/signaling.2.050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A Brief Update on STAT3 Signaling: Current Challenges and Future Directions in Cancer Treatment
Due to its importance in a wide range of cellular processes, including cell proliferation, apoptosis, and immune evasion, the signal transducer and activator of transcription (STAT) 3 signaling pathway has been studied intensively over the past few decades. Dysregulation of the STAT3 signaling pathway is closely associated with initiation and development of various types of hematologic or solid malignancies (approximately 70% of those appearing in humans) [1].